Magrangeas, F.

patient bortezomib myeloma neuropathy intron association study analysis coding-nonsynonymou discovery factor validation trial hovon -65/gmmg trial czech republic hovon table pointwise myeloma patients disease onset polymorphism ifm 2005-01 trial treatment -65/gmmg effect grade cancer myeloma foundation development pathway czech nucleotide republic bortezomib metabolizing genes haematologica j hum genet j clin oncol figure nucleotide polymorphisms dataset p value foundation pathway analysis χ2 association analysis .11 risk factors nucleotide polymorphism onset bipn 0.44 significance 0.66 result value system panel 2005-01 research frequency locus corthal group 0.43 enrichment richardson multiplicity correction cycle rs 619824 mm patients allele frequency sample correction 0.97 0.63 facon t 56 snps sonneveld p lancet oncol cyp 17a sonneveld